According to Zacks, “Ampio Pharmaceuticals, Inc. develops proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. Principal products offered by the Company include Optina, an oral drug for the treatment of diabetic retinopathy and macular edema; and Vasaloc, an oral drug for the treatment of diabetic nephropathy. Ampio Pharmaceuticals, Inc. is based in Greenwood Village, Colorado. “
Separately, Roth Capital restated a “buy” rating and issued a $4.00 price objective on shares of Ampio Pharmaceuticals in a report on Friday, January 22nd.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last posted its quarterly earnings results on Tuesday, March 2nd. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). As a group, analysts anticipate that Ampio Pharmaceuticals will post -0.09 EPS for the current fiscal year.
In other Ampio Pharmaceuticals news, COO Holli Cherevka sold 74,631 shares of the business’s stock in a transaction on Tuesday, April 27th. The shares were sold at an average price of $2.00, for a total transaction of $149,262.00. Following the completion of the sale, the chief operating officer now directly owns 30,000 shares in the company, valued at approximately $60,000. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Dan Stokely sold 40,000 shares of the stock in a transaction on Tuesday, March 16th. The shares were sold at an average price of $1.83, for a total value of $73,200.00. Following the transaction, the chief financial officer now directly owns 68,315 shares in the company, valued at $125,016.45. The disclosure for this sale can be found here. Insiders have sold 137,894 shares of company stock worth $268,988 over the last ninety days. 3.60% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the business. BlackRock Inc. raised its position in Ampio Pharmaceuticals by 96.3% in the fourth quarter. BlackRock Inc. now owns 3,104,227 shares of the specialty pharmaceutical company’s stock worth $4,936,000 after acquiring an additional 1,522,584 shares during the period. Willis Investment Counsel purchased a new position in Ampio Pharmaceuticals during the fourth quarter valued at $1,929,000. Chicago Capital LLC bought a new stake in Ampio Pharmaceuticals during the first quarter valued at about $187,000. ExodusPoint Capital Management LP bought a new stake in Ampio Pharmaceuticals during the fourth quarter valued at about $166,000. Finally, Jane Street Group LLC purchased a new stake in Ampio Pharmaceuticals in the fourth quarter worth about $149,000. 9.91% of the stock is currently owned by institutional investors and hedge funds.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.
Featured Article: The Discount Rate – What You Need to Know
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.